US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
WO2000042213A1
(en)
|
1999-01-13 |
2000-07-20 |
The Research Foundation Of State University Of New York |
A novel method for designing protein kinase inhibitors
|
SK287142B6
(sk)
*
|
2000-02-15 |
2010-01-07 |
Sugen, Inc. |
Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
CA2410509A1
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
CA2414468A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
ES2282299T3
(es)
|
2000-10-20 |
2007-10-16 |
EISAI R&D MANAGEMENT CO., LTD. |
Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
|
US6677368B2
(en)
*
|
2000-12-20 |
2004-01-13 |
Sugen, Inc. |
4-aryl substituted indolinones
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
EP1247809A3
(en)
*
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazine compounds useful as sorbitol dehydrogenase inhibitors
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
EP1471907B1
(en)
*
|
2001-06-29 |
2008-07-16 |
AB Science |
Use of c-kit inhibitors for treating autoimmune diseases
|
AR038957A1
(es)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
EP3168218B1
(en)
|
2001-08-15 |
2018-11-14 |
Pharmacia & Upjohn Company LLC |
A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
|
WO2003022815A1
(en)
*
|
2001-09-10 |
2003-03-20 |
Sugen, Inc. |
3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
|
JP2005508953A
(ja)
*
|
2001-10-10 |
2005-04-07 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としての3−[4−(置換ヘテロサイクリル)−ピロール−2−イルメチリデン]−2−インドリノン誘導体
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US20030080191A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Allen Lubow |
Method and apparatus for applying bar code information to products during production
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US20050131733A1
(en)
*
|
2001-12-17 |
2005-06-16 |
Allen Lubow |
Sealable individual bar coded packets
|
US7156308B2
(en)
*
|
2001-12-17 |
2007-01-02 |
International Barcode Corporation |
Double-sided bar code doubling as a single bar code
|
IL162203A0
(en)
|
2001-12-27 |
2005-11-20 |
Theravance Inc |
Indolinone derivatives useful as protein inase inhibitors
|
CA2475455A1
(en)
|
2002-02-15 |
2003-08-28 |
Pharmacia & Upjohn Company |
Process for preparing indolinone derivatives
|
US20040018528A1
(en)
*
|
2002-05-17 |
2004-01-29 |
Sugen, Inc. |
Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
WO2004016211A2
(en)
*
|
2002-08-08 |
2004-02-26 |
Vanderbilt University |
Pi3k antagonists as radiosensitizers
|
US7195876B2
(en)
*
|
2002-08-09 |
2007-03-27 |
Theravance, Inc. |
Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
|
US20040121407A1
(en)
*
|
2002-09-06 |
2004-06-24 |
Elixir Pharmaceuticals, Inc. |
Regulation of the growth hormone/IGF-1 axis
|
HN2003000272A
(es)
*
|
2002-09-10 |
2008-07-29 |
Pharmacia Italia Spa |
Formulaciones que comprenden un compuesto de indolinona
|
US7626031B2
(en)
*
|
2002-11-15 |
2009-12-01 |
Symphony Evolution, Inc. |
Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
US20040209937A1
(en)
*
|
2003-02-24 |
2004-10-21 |
Sugen, Inc. |
Treatment of excessive osteolysis with indolinone compounds
|
US7452913B2
(en)
*
|
2003-02-24 |
2008-11-18 |
Pharmacia & Upjohn Company |
Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
JPWO2004080462A1
(ja)
*
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE10334582A1
(de)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Verfahren zur Herstellung von Maleinsäureanhydrid
|
WO2005023765A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Pharmacia & Upjohn Company Llc |
Method for catalyzing amidation reactions by the presence of co2
|
SI1670785T1
(sl)
*
|
2003-10-02 |
2010-10-29 |
Pharmacia & Upjohn Co Llc |
Soli in polimorfi spojine indolinona, substituirani s pirolom
|
PT1680140E
(pt)
*
|
2003-10-16 |
2011-05-31 |
Imclone Llc |
Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
|
JP4890255B2
(ja)
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
EP1686987A4
(en)
*
|
2003-11-26 |
2009-02-25 |
Scripps Research Inst |
ADVANCED PROTEIN KINASE HEMMER ON INDOLINO BASIS
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
US20050152943A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Medtronic Vascular, Inc. |
Medical devices to treat or inhibit restenosis
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
SE0401790D0
(sv)
*
|
2004-07-07 |
2004-07-07 |
Forskarpatent I Syd Ab |
Tamoxifen response in pre- and postmenopausal breast cancer patients
|
US20060009510A1
(en)
*
|
2004-07-09 |
2006-01-12 |
Pharmacia & Upjohn Company Llc |
Method of synthesizing indolinone compounds
|
GEP20104906B
(en)
*
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
CN100432071C
(zh)
*
|
2004-11-05 |
2008-11-12 |
中国科学院上海药物研究所 |
取代1h-吲哚-2-酮类化合物及其制备方法和用途
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
CA2602316A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
MX2007014087A
(es)
*
|
2005-05-12 |
2008-02-07 |
Pfizer |
Combinaciones y procedimientos para usar un compuesto de indolinona.
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
WO2006127926A2
(en)
|
2005-05-23 |
2006-11-30 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
EP1893194A4
(en)
*
|
2005-05-26 |
2009-07-01 |
Scripps Research Inst |
IMPROVED PROTEIN KINASE HEMMER ON INDOLINON BASE
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
PT2447283E
(pt)
|
2005-09-07 |
2015-10-08 |
Pfizer |
Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
|
KR101050906B1
(ko)
*
|
2005-09-19 |
2011-07-20 |
화이자 프로덕츠 인크. |
피롤 치환된 2-인돌리논의 고체 염 형태
|
CN101316590B
(zh)
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
UA96139C2
(xx)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1)
|
KR20080083341A
(ko)
*
|
2005-12-29 |
2008-09-17 |
더 스크립스 리서치 인스티튜트 |
인돌리논의 아미노산 유도체 기재의 단백질 키나제 억제제
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101007801A
(zh)
*
|
2006-01-27 |
2007-08-01 |
上海恒瑞医药有限公司 |
吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
KR20080110912A
(ko)
|
2006-04-19 |
2008-12-19 |
노파르티스 아게 |
인다졸 화합물 및 cdc7의 억제 방법
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
RU2448708C3
(ru)
*
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
DE102006024834B4
(de)
*
|
2006-05-24 |
2010-07-01 |
Schebo Biotech Ag |
Neue Indol-Pyrrol-Derivate und deren Verwendungen
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
US20080025946A1
(en)
|
2006-07-13 |
2008-01-31 |
Sivakumar Pallavur V |
Interleukin 21 and tyrosine kinase inhibitor combination therapy
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
US8044049B2
(en)
|
2006-08-04 |
2011-10-25 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivative and use thereof
|
SI2057156T1
(sl)
*
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
JP5368096B2
(ja)
|
2006-08-28 |
2013-12-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌に対する抗腫瘍剤
|
CN101553482B
(zh)
|
2006-09-15 |
2013-11-20 |
艾科睿制药公司 |
激酶抑制剂化合物
|
EP2130829A4
(en)
*
|
2006-11-06 |
2010-12-01 |
Theravalues Corp |
NEW HYDROXYINDOLE DERIVATIVE
|
AU2007316417B2
(en)
|
2006-11-06 |
2013-08-22 |
Tolero Pharmaceuticals, Inc. |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
JP5542445B2
(ja)
|
2006-12-04 |
2014-07-09 |
江▲蘇▼先声▲薬▼物研究有限公司 |
3−ピロロシクロへキシリデン−2−ジヒドロインドリノン誘導体およびその用途
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
CA2677365A1
(en)
|
2007-02-06 |
2008-08-14 |
Pfizer Inc. |
2-amino-5, 7-dihydro-6h-pyrrolo [3, 4-d] pyrimidine derivatives as hsp- 90 inhibitors for treating cancer
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
US20090004213A1
(en)
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
US20090042906A1
(en)
*
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
WO2008145398A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Pfizer Italia S.R.L. |
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
CL2008001626A1
(es)
|
2007-06-05 |
2009-06-05 |
Takeda Pharmaceuticals Co |
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
|
WO2009025358A1
(ja)
|
2007-08-23 |
2009-02-26 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
US20090062368A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
EP3037419B1
(en)
*
|
2007-09-06 |
2019-09-04 |
Boston Biomedical, Inc. |
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2220072A2
(en)
|
2007-11-21 |
2010-08-25 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
US20100256392A1
(en)
*
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
US8389562B2
(en)
*
|
2007-12-12 |
2013-03-05 |
Medichem, S.A. |
Polymorphic forms of a 3-pyrrole substituted 2-indolinone
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
CA2710122A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
US20100324087A1
(en)
*
|
2008-01-29 |
2010-12-23 |
Eisai R&D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
CA2713112A1
(en)
*
|
2008-02-13 |
2009-08-20 |
Ratiopharm Gmbh |
Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
|
EP2090306A1
(en)
|
2008-02-13 |
2009-08-19 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
EP2113248A1
(en)
|
2008-04-29 |
2009-11-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
|
CN101255154B
(zh)
*
|
2008-02-18 |
2011-09-07 |
靳广毅 |
一种取代的2-吲哚啉酮衍生物和制备方法及其应用
|
AU2009215377A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
WO2009124037A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
EP2280960A1
(en)
*
|
2008-04-16 |
2011-02-09 |
Natco Pharma Limited |
Novel polymorphic forms of sunitinib base
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
CA2725001C
(en)
*
|
2008-05-23 |
2014-05-13 |
Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
Dihydroindolone derivatives
|
US8263547B2
(en)
*
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
ES2392762T3
(es)
*
|
2008-06-13 |
2012-12-13 |
Medichem, S.A. |
Procedimiento para preparar una sal de malato de 2-indolinona sustituida con 3-pirrol
|
US8501962B2
(en)
|
2008-06-23 |
2013-08-06 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
EP2138167A1
(en)
*
|
2008-06-24 |
2009-12-30 |
ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009156837A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Medichem, S.A. |
Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
|
WO2010002933A1
(en)
*
|
2008-06-30 |
2010-01-07 |
Cylene Pharmaceuticals, Inc. |
Oxindole compounds
|
US20110200612A1
(en)
|
2008-06-30 |
2011-08-18 |
Michael Schuster |
Treatment of eye diseases and excessive neovascularization using combined therapy
|
DE102008031038A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Sutent zur Anwendung in der Organtransplantation
|
CA2729253A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Generics [Uk] Limited |
Novel process
|
CA2730079A1
(en)
*
|
2008-07-10 |
2010-01-14 |
Generics [Uk] Limited |
Processes for the preparation of crystalline forms of sunitinib malate
|
US8618309B2
(en)
|
2008-07-24 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
WO2010010454A2
(en)
|
2008-07-24 |
2010-01-28 |
Medichem, S.A. |
Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
|
WO2010017541A2
(en)
|
2008-08-08 |
2010-02-11 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
JP2012500838A
(ja)
*
|
2008-08-25 |
2012-01-12 |
ジェネリクス・(ユーケー)・リミテッド |
スニチニブの新規な多形およびその調製方法
|
AU2009286520A1
(en)
*
|
2008-08-25 |
2010-03-04 |
Generics [Uk] Limited |
Crystalline form of sunitinib and processes for its preparation
|
US20110159023A1
(en)
*
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
RS54233B1
(en)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
|
RU2535975C2
(ru)
*
|
2008-09-05 |
2014-12-20 |
Империал Инновейшнз Лимитед |
Производные изатина для применения в качестве агентов визуализации in vivo
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
AR073807A1
(es)
*
|
2008-10-10 |
2010-12-01 |
Medichem Sa |
Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
EP2399921B1
(en)
|
2008-12-01 |
2015-08-12 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
WO2010076805A2
(en)
|
2009-01-02 |
2010-07-08 |
Hetero Research Foundation |
Novel polymorphs of sunitinib malate
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
EP3100745B1
(en)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
WO2010098888A1
(en)
*
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010103094A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
WO2010120386A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2255792A1
(en)
|
2009-05-20 |
2010-12-01 |
Ratiopharm GmbH |
Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2264027A1
(en)
*
|
2009-05-27 |
2010-12-22 |
Ratiopharm GmbH |
Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
FR2948940B1
(fr)
|
2009-08-04 |
2011-07-22 |
Servier Lab |
Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
CA2771675A1
(en)
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
WO2011033472A1
(en)
|
2009-09-16 |
2011-03-24 |
Ranbaxy Laboratories Limited |
Salts of sunitinib
|
CN102666545B
(zh)
|
2009-10-20 |
2016-04-06 |
塞尔卓姆有限公司 |
作为jak抑制剂的杂环吡唑并嘧啶类似物
|
US20120271056A1
(en)
|
2009-11-12 |
2012-10-25 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
|
US8916716B2
(en)
|
2009-11-19 |
2014-12-23 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
WO2011095802A1
(en)
|
2010-02-02 |
2011-08-11 |
Generics [Uk] Limited |
Hplc method for analyzing sunitinib
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
BR112012019635A2
(pt)
|
2010-02-22 |
2016-05-03 |
Hoffmann La Roche |
compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
CA2792039A1
(en)
|
2010-03-04 |
2011-09-09 |
Ranbaxy Laboratories Limited |
Process for the direct preparation of malic acid salt of sunitinib
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
EP2545034A1
(en)
|
2010-03-10 |
2013-01-16 |
Synthon B.V. |
A process for amidation of pyrrole carboxylate compounds
|
AU2011228765A1
(en)
|
2010-03-18 |
2012-10-11 |
Ranbaxy Laboratories Limited |
Process for the preparation of malic acid salt of sunitinib
|
WO2011119777A2
(en)
|
2010-03-23 |
2011-09-29 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
JP2013525392A
(ja)
|
2010-04-30 |
2013-06-20 |
セルゾーム リミティッド |
Jak阻害剤としてのピラゾール化合物
|
WO2011138565A1
(fr)
|
2010-05-05 |
2011-11-10 |
Biorebus |
Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
|
EP2392324A1
(en)
|
2010-06-01 |
2011-12-07 |
Societe De Coordination De Recherches Therapeutiques |
Rhenium complexes and their pharmaceutical use
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
MX2013000083A
(es)
|
2010-07-09 |
2013-02-26 |
Genentech Inc |
Anticuerpos de anti-neuropilina y metodos de uso.
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
JP2013534233A
(ja)
|
2010-08-20 |
2013-09-02 |
セルゾーム リミティッド |
選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
CN103328465B
(zh)
|
2010-11-01 |
2015-05-27 |
神隆(昆山)生化科技有限公司 |
使用2-甲硅烷氧基-吡咯类制备3-((吡咯-2-基)亚甲基)-2-吡咯酮类的方法
|
WO2012059941A1
(en)
*
|
2010-11-04 |
2012-05-10 |
Ind-Swift Laboratories Limited |
Process for preparation of sunitinib malate and salts thereof
|
CA2815330A1
(en)
|
2010-11-09 |
2012-05-18 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as tyk2 inhibitors
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
EP2640360A2
(en)
|
2010-11-19 |
2013-09-25 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并[5,4-b]吡啶-5-基化合物
|
JP6002149B2
(ja)
|
2010-12-23 |
2016-10-05 |
ネクター セラピューティクス |
ポリマー−スニチニブコンジュゲート
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
ES2611885T3
(es)
|
2011-01-31 |
2017-05-11 |
Novartis Ag |
Derivados heterocíclicos novedosos
|
MY183977A
(en)
|
2011-02-15 |
2021-03-17 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
JP5937111B2
(ja)
|
2011-02-17 |
2016-06-22 |
カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited |
Fak阻害剤
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
US8630703B2
(en)
|
2011-03-09 |
2014-01-14 |
Technion Research & Development Foundation Limited |
Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
|
CN102115469A
(zh)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
吲哚啉-2-酮类衍生物的制备和用途
|
US20140163023A1
(en)
|
2011-04-04 |
2014-06-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
MX2013011481A
(es)
*
|
2011-04-08 |
2014-02-17 |
Beta Pharma Inc |
Nuevos inhibidores de cinasa de proteina de indolinona.
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
CN102898402B
(zh)
*
|
2011-04-26 |
2016-01-20 |
北京大学 |
一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
EP2739252A4
(en)
|
2011-08-05 |
2015-08-12 |
Forsight Vision4 Inc |
SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
|
EP2760863A1
(en)
|
2011-09-20 |
2014-08-06 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
|
AU2012311458B2
(en)
|
2011-09-21 |
2016-02-04 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
|
US9242993B2
(en)
|
2011-10-07 |
2016-01-26 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
CN102499917B
(zh)
|
2011-10-25 |
2014-12-17 |
澳门大学 |
吲哚酮类化合物在制备神经保护药物中的应用
|
PL2771342T3
(pl)
|
2011-10-28 |
2016-11-30 |
|
Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
|
CN103130774B
(zh)
*
|
2011-11-22 |
2016-06-22 |
齐鲁制药有限公司 |
具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
CN104169272A
(zh)
|
2011-12-23 |
2014-11-26 |
赛尔佐姆有限公司 |
作为激酶抑制剂的嘧啶-2,4-二胺衍生物
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN102491932A
(zh)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
一种3-吲哚啉酮类衍生物及其制备方法及其应用
|
EP2828251B1
(en)
|
2012-03-23 |
2018-10-31 |
Laurus Labs Limited |
An improved process for the preparation of sunitinib and its acid addition salts thereof
|
IN2014MN02105A
(xx)
|
2012-04-20 |
2015-09-11 |
Annji Pharm Co Ltd |
|
CN102653521B
(zh)
*
|
2012-04-27 |
2014-08-06 |
首都师范大学 |
吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
|
PL399027A1
(pl)
|
2012-04-27 |
2013-10-28 |
Instytut Farmaceutyczny |
Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
SG10201608469RA
(en)
|
2012-05-16 |
2016-11-29 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
CA2882158A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
CA2904152A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
DK2970205T3
(da)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CN104119321B
(zh)
*
|
2013-04-28 |
2017-09-08 |
齐鲁制药有限公司 |
二氢吲哚酮衍生物的二马来酸盐及其多晶型物
|
AU2014266223B2
(en)
|
2013-05-14 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
FR3008411B1
(fr)
*
|
2013-07-12 |
2015-07-03 |
Servier Lab |
Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
|
EP3039424B1
(en)
|
2013-08-28 |
2020-07-29 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9604968B2
(en)
|
2013-10-18 |
2017-03-28 |
Sun Pharmaceutical Industries Limited |
Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
|
US9278955B2
(en)
|
2013-10-18 |
2016-03-08 |
Sun Pharmaceutical Industries Limited |
Ascorbic acid salt of sunitinib
|
JP2016535989A
(ja)
|
2013-11-01 |
2016-11-24 |
ファイザー・インク |
前立腺関連抗原を発現させるためのベクター
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
CN104829596B
(zh)
|
2014-02-10 |
2017-02-01 |
石家庄以岭药业股份有限公司 |
吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
|
CN103923014A
(zh)
*
|
2014-05-05 |
2014-07-16 |
宁夏宝马药业有限公司 |
环肌酸制备方法
|
EP3177289A4
(en)
|
2014-08-08 |
2018-03-21 |
Forsight Vision4, Inc. |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
SG11201705767PA
(en)
|
2015-01-13 |
2017-08-30 |
Univ Kyoto |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
BR112018005589A2
(pt)
|
2015-09-22 |
2018-10-09 |
Graybug Vision Inc |
“composto, composição farmaceuticamente aceitável, e, uso de um composto”
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
EP3370719A1
(en)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
BR112018009644A2
(pt)
|
2015-11-12 |
2018-11-06 |
Graybug Vision Inc |
micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CN109072241A
(zh)
|
2016-02-08 |
2018-12-21 |
维特里萨医疗公司 |
具有改善的玻璃体内半衰期的组合物及其用途
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018081530A1
(en)
|
2016-10-28 |
2018-05-03 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating ezh2-mediated cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
WO2018106870A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
MX2019007332A
(es)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Péptidos indicadores y métodos para caracterizar sensibilidad.
|
CN106916143B
(zh)
*
|
2017-03-14 |
2019-09-27 |
哈尔滨医科大学 |
一种预防和治疗冠心病的药物及其应用
|
RU2019133337A
(ru)
|
2017-03-23 |
2021-04-23 |
Грейбуг Вижн, Инк. |
Лекарственные средства и композиции для лечения глазных нарушений
|
AU2018265415A1
(en)
|
2017-05-10 |
2019-10-31 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US20200353076A1
(en)
|
2017-09-18 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
EP3762381A4
(en)
|
2018-03-06 |
2022-01-05 |
Icahn School of Medicine at Mount Sinai |
SERINE THREONINE KINASE (AKT) DEGRADATION / INTERRUPTION COMPOUNDS AND METHODS OF USE
|
EP3539536A1
(en)
|
2018-03-15 |
2019-09-18 |
MH10 Spolka z ograniczona odpowiedzialnoscia |
A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
|
WO2020216450A1
(en)
|
2019-04-25 |
2020-10-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous sunitinib
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
WO2020227325A1
(en)
|
2019-05-06 |
2020-11-12 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
CA3152674A1
(en)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivatives for fgfr inhibitor and preparation method thereof
|
US20220401436A1
(en)
|
2019-11-08 |
2022-12-22 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN111233841A
(zh)
*
|
2020-03-17 |
2020-06-05 |
湖北扬信医药科技有限公司 |
一种舒尼替尼有关物质及其制备方法和用途
|
WO2023278424A1
(en)
*
|
2021-06-28 |
2023-01-05 |
The Regents Of The University Of California |
Methods for treating and ameliorating t cell related diseases
|
CN113717159A
(zh)
*
|
2021-09-16 |
2021-11-30 |
中国药科大学 |
吲哚酮类化合物及其药物组合物、制备方法及用途
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024017372A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
成都百裕制药股份有限公司 |
一种吲哚酮衍生物及其应用
|